Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some mechanistic and adverse-reaction claims align with the provided label (e.g., HMG-CoA reductase inhibition, common GI symptoms, myalgia/myopathy). However, several efficacy/benefit and risk-allocation statements are either unsupported by the provided label text or go beyond what is explicitly stated (e.g., HDL-mediated removal language, CoQ10 rationale, quantified muscle-pain rate, and leg weakness risk phrasing). Several recommendations (dose reduction/switch/add CoQ10) are not supported in the supplied label excerpts.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a cholesterol-lowering medication used to lower cholesterol levels in the blood.
Supported generally by Section 1.2 (reduces total-C, LDL-C, TG and increases HDL-C) and Section 14.2 (reduces total-C, LDL-C, VLDL-C, apo B, TG and increases HDL-C).
Lipitor belongs to the class of medications known as HMG-CoA reductase inhibitors.
Supported by Section 12.1 (selective, competitive inhibitor of HMG-CoA reductase).
HMG-CoA reductase inhibitors work by blocking the production of cholesterol in the liver.
Supported by Section 12.1 (inhibitor of HMG-CoA reductase) as provided; the provided label describes inhibition of HMG-CoA reductase and downstream lipid effects.
Lipitor can cause muscle pain or weakness.
Supported by Section 6.1 common discontinuation adverse reaction myalgia (0.7%) and Section 5.1 myopathy description.
Lipitor can cause headaches.
Not explicitly supported by the provided label excerpts for headaches; therefore treated as unsupported/uncertain below if not listed in adverse reactions excerpts.
Lipitor can cause diarrhea.
Supported by Section 6.1 (diarrhea 0.5% leading to discontinuation; and diarrhea 6.8% in trials).
Lipitor can cause nausea.
Supported by Section 6.1 (nausea 0.4% leading to discontinuation).
Lipitor can cause abdominal pain.
Not explicitly supported by the provided label excerpts; therefore treated as unsupported below if not present.
Lipitor can cause fatigue.
Supported by Section 6.2 postmarketing adverse reactions including fatigue.
The exact cause of leg weakness in Lipitor users is not fully understood.
Not supported explicitly in the provided label excerpts; the label discusses risk factors and adverse reaction mechanisms at a high level but does not provide this specific phrasing. Marked as unsupported below.
Leg weakness in Lipitor users can manifest as fatigue or weakness.
Partially supported by adverse reaction reports of fatigue (Section 6.2) and general myopathy descriptions (Section 5.1), but the specific mapping to 'leg weakness' is not explicitly stated in provided excerpts. Marked as partially supported/unsupported below.
Pravastatin (Pravachol) is listed as an alternative medication to Lipitor.
Not supported by the provided label excerpts; the label excerpts do not list alternatives.
Simvastatin (Zocor) is listed as an alternative medication to Lipitor.
Not supported by the provided label excerpts; the label excerpts do not list alternatives.
Rosuvastatin (Crestor) is listed as an alternative medication to Lipitor.
Not supported by the provided label excerpts; the label excerpts do not list alternatives.
Ezetimibe (Zetia) is listed as an alternative medication to Lipitor.
Not supported by the provided label excerpts; the label excerpts do not list alternatives.
Unsupported Statements
By reducing cholesterol levels, Lipitor can help prevent heart disease.
The provided label supports cardiovascular risk reduction endpoints (myocardial infarction, stroke, revascularization, angina, CHF hospitalization) in Section 1.1, but does not use the broad phrase 'prevent heart disease' in the provided label text. Treated as unsupported wording.
By reducing cholesterol levels, Lipitor can help prevent strokes.
The label supports reducing risk of stroke (Section 1.1) but the statement attributes causality specifically to 'reducing cholesterol levels' rather than using the label’s indicated outcomes; the provided text does not make this causal linkage in that phrasing.
Lipitor can help prevent other cardiovascular conditions.
Section 1.1 lists specific endpoints (MI, stroke, revascularization procedures and angina, CHF hospitalization) but the statement is overly general and not directly supported by the provided label excerpts.
Lipitor blocks the enzyme HMG-CoA reductase responsible for producing cholesterol in the liver.
Section 12.1 supports HMG-CoA reductase inhibition; however, the provided excerpts do not explicitly state 'in the liver' or 'responsible for producing cholesterol in the liver' in that exact formulation.
Lipitor decreases the amount of cholesterol produced in the liver.
The provided excerpts emphasize lipid effects and inhibition (Sections 12.1, 14.2) but do not explicitly state 'produced in the liver' or 'decreases amount produced in the liver.'
Lipitor helps to increase levels of high-density lipoprotein (HDL), described as “good” cholesterol.
Section 1.2 and 14.2 state it increases HDL-C; however, the provided label excerpts do not describe HDL as 'good cholesterol' in those words.
Lipitor can help remove excess cholesterol from the bloodstream via increased HDL.
The provided label excerpts state increases in HDL-C but do not describe 'removal of excess cholesterol from the bloodstream via increased HDL' or that mechanism.
Lipitor can cause headaches.
Headaches are not listed in the provided adverse reaction excerpts (Sections 6.1 and 6.2) provided.
Lipitor can cause abdominal pain.
Abdominal pain is not listed in the provided adverse reaction excerpts (Sections 6.1 and 6.2) provided.
Leg weakness is a potential side effect of Lipitor.
The label discusses myopathy/myalgia and other adverse reactions but does not explicitly use the term 'leg weakness' as a named adverse reaction in the provided excerpts.
Muscle pain or weakness is described as a common side effect of statin medications, including Lipitor.
The label provides 'myalgia' incidence and myopathy description for Lipitor, but it does not describe 'weakness' as a common side effect in the provided excerpts.
A study reported that muscle pain or weakness was reported by 1.5% of patients taking Lipitor.
The provided label excerpts give myalgia at 0.7% leading to discontinuation (Section 6.1) but do not provide a '1.5%' figure for muscle pain/weakness.
It is thought that statins, including Lipitor, can cause a decrease in coenzyme Q10 (CoQ10) levels.
CoQ10 is not mentioned in the provided labeling excerpts.
CoQ10 is described as a substance that helps generate energy in muscles.
CoQ10 description is not present in the provided labeling excerpts.
A decrease in CoQ10 can lead to muscle weakness.
CoQ10-related causal statements are not supported in the provided labeling excerpts.
A decrease in CoQ10 can lead to muscle fatigue.
CoQ10-related causal statements are not supported in the provided labeling excerpts.
A decrease in CoQ10 can lead to muscle pain.
CoQ10-related causal statements are not supported in the provided labeling excerpts.
Older adults are at higher risk of experiencing leg weakness while taking Lipitor.
The provided label excerpts do not explicitly state older adults have higher risk of 'leg weakness.' They discuss risk factors for rhabdomyolysis/myopathy generally (Section 5.1), but not this specific claim.
People with pre-existing muscle or nerve damage are at higher risk of experiencing leg weakness while taking Lipitor.
The provided label excerpts list risk factor examples for renal failure secondary to rhabdomyolysis (Section 5.1) but do not explicitly mention pre-existing muscle or nerve damage or 'leg weakness' in the provided text.
Those taking high doses of Lipitor are at higher risk of experiencing leg weakness.
The provided excerpts discuss higher doses in context of drug interactions increasing risk of myopathy/rhabdomyolysis (Section 5.1), but does not explicitly state 'high doses increase leg weakness.'
Patients with kidney or liver disease are at higher risk of experiencing leg weakness.
The provided excerpts discuss predisposition to renal failure secondary to rhabdomyolysis (Section 5.1) and liver dysfunction guidance/contraindication (Section 4.1, 5.2), but do not explicitly tie 'kidney or liver disease' to higher risk of 'leg weakness' in the provided text.
Leg weakness in Lipitor users can manifest as muscle pain or cramping.
Myalgia is supported (Section 6.1; Section 5.1 myopathy), but the specific mapping to 'leg weakness' and 'cramping' is not explicitly stated in the provided excerpts.
Leg weakness in Lipitor users can manifest as difficulty walking or climbing stairs.
The provided label excerpts do not describe difficulty walking/climbing stairs.
Leg weakness in Lipitor users can manifest as muscle spasms or twitching.
The provided label excerpts do not describe muscle spasms or twitching.
If a patient taking Lipitor experiences leg weakness symptoms, a doctor may recommend reducing the dose of Lipitor.
The provided excerpts describe temporarily withholding/discontinuing in acute serious myopathy (Section 5.1) and dose reduction/withdrawal related to persistent ALT/AST elevations (Section 5.2), but do not explicitly state dose reduction for 'leg weakness symptoms.'
If a patient taking Lipitor experiences leg weakness symptoms, a doctor may recommend switching to a different statin medication.
No switching recommendation is provided in the supplied excerpts.
If a patient taking Lipitor experiences leg weakness symptoms, a doctor may recommend adding a CoQ10 supplement to the regimen.
CoQ10 is not mentioned in the provided labeling excerpts.
If a patient taking Lipitor experiences leg weakness symptoms, a doctor may recommend monitoring muscle function and liver enzymes.
The provided excerpts for skeletal muscle (Section 5.1) do not specify monitoring 'muscle function,' and liver monitoring is discussed generally for initiation and dose changes (Section 5.2), but the statement is not explicitly tied to 'leg weakness symptoms.'
Pravastatin (Pravachol) is listed as an alternative medication to Lipitor.
Alternative medications are not listed in the provided labeling excerpts.
Simvastatin (Zocor) is listed as an alternative medication to Lipitor.
Alternative medications are not listed in the provided labeling excerpts.
Rosuvastatin (Crestor) is listed as an alternative medication to Lipitor.
Alternative medications are not listed in the provided labeling excerpts.
Ezetimibe (Zetia) is listed as an alternative medication to Lipitor.
Alternative medications are not listed in the provided labeling excerpts.
Contradictions
Important Omissions
No mention of Lipitor contraindications relevant to safe use (active liver disease; pregnancy; nursing) or how/when to discontinue in those settings.
Importance:
Moderate
No mention of required/label-specified liver function testing schedule (prior to and at 12 weeks after initiation and after any dose increase) and management threshold for ALT/AST >3x ULN.
Importance:
Moderate
No mention of label-specified drug-interaction dosing limits (e.g., limiting LIPITOR to 10 mg with cyclosporine; caution when dose exceeds 20 mg with clarithromycin/itraconazole/HIV protease inhibitors; grapefruit juice guidance).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements extend beyond the provided label (CoQ10-related rationale; alternative therapy/add-on recommendations; leg-weakness-specific risk language; and switching/dose-reduction guidance for leg weakness). While some adverse-reaction categories align, unsupported management recommendations could mislead clinical decision-making relative to the label’s described withholding/discontinuation and monitoring approach.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Multiple claims are unsupported by the provided Lipitor label excerpts, especially CoQ10-related content and leg-weakness-specific management/risk phrasing.
Suggested Improvement
Constrain statements to the provided label wording and endpoints (Sections 1.1/1.2/12.1/5.1/5.2/6.1/6.2/7/14). Remove CoQ10 mechanism and supplement/switch recommendations unless included in the label text. Replace 'leg weakness' mapping and numerical/incidence claims with label-supported myalgia/myopathy language and the actual incidence figures provided.